1d
Gene Editing Has Struggled To Go Commercial. This Nobel Laureate Has A $1 Billion Plan To Fix That.
Crispr’s ability to cut genetic code like scissors has just started to turn into medicines. Now, gene editing pioneer ...
Zacks Investment Research on MSN
CRISPR Therapeutics AG (CRSP) is attracting investor attention: Here is what you should know
CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of ...
In this week’s edition of InnovationRx, we look at Jennifer Doudna’s $1 billion plan to bring Crispr gene editing to the real ...
CRISPR Therapeutics AG recently reported its fourth-quarter and full-year 2025 results, showing revenue falling to US$0.864 million in Q4 and US$3.51 million for the year, alongside wider net losses ...
Intellia Therapeutics, Inc. (NASDAQ:NTLA) ranks among the best innovative stocks to buy according to Wall Street analysts.
Detailed price information for Ultragenyx Pharmaceu (RARE-Q) from The Globe and Mail including charting and trades.
ARKK is having a rough start to 2026. After closing 2025 with a 35.49% return that crushed the S&P 500, Cathie Wood’s ...
ARK Invest’s Q4 2025 13F: top holdings, buys/sells, and shifts in TSLA, COIN, SHOP, ROKU & genomics/AI/crypto bets. Read here for a detailed analysis.
Even in the best-case scenario, it’s incredibly disruptive. And this is where you’ve been quoted saying that A.I. will disrupt 50 percent of entry-level white-collar jobs. On a five-year time horizon, ...
CRISPR Therapeutics is commercially validated with CASGEVY but remains financially unproven and operates at a loss. Click to read this CRSP stock update.
CRISPR Therapeutics’ fourth quarter was relatively disappointing. As a biotech start-up still in its infancy though, these ...
2026 could be a big year for this company.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results